The tablets will be manufactured at APL Healthcare unit IV, a wholly-owned subsidiary of the company, and will be launched immediately. Shares of Aurobindo Pharma Ltd ended at ₹1,467, up by ₹26.70, or 1.85%, on the BSE today, June 4.Read More
Aurobindo Pharma gets final FDA nod for tofacitinib tablets which target rheumatoid arthritis
- by stefan